Alpaca nanobodies show promising results in CAR-T solid tumor treatment

Scientists from Boston Children’s Hospital and Massachusetts Institute of Technology (MIT) have used alpaca-derived nanobodies to create a novel approach to CAR T cell therapy that addresses the challenge of treating patients with solid tumor cancers. Currently, CAR-T cell immunotherapy has been applied to the treatment of non-solid tumors such as acute lymphoblastic leukemia (ALL).

New Review Article Outlines Mechanisms of Resistance to CAR T Cell Therapy

Following successful clinical studies, the FDA and regulatory authorities around the world have approved the use of axicabtagene ciloleucel (Yescarta™) for patients with large-B-cell lymphomas and tisagenlecleucel (Kymriah™) for adults with certain types of non-Hodgkin lymphoma. Despite its success as a novel way of treating cancer, physician scientists are realizing that 30%-50% of patients who

The Akron Team Participates in the 4th Annual Innate Killer Summit

The Akron team recently attended the 4th Innate Killer Summit, held in in San Diego, California. The conference provided an excellent opportunity to participate in presentations and workshops covering cutting-edge research, recent clinical data, and commercial developments in the growing NK cell therapy market. More than 250 attendees collaborated and shared knowledge on ways we

New methods to improve cryopreservation for immunotherapies using a bioinspired solution

The preservation of biological samples is critical to the success of experimental studies and clinical treatments in the emergent field of immunotherapy. Cryopreservation – keeping cells at sub-zero temperatures – slows metabolic activity significantly, enabling storage and transportation, as well as a return to functionality upon thaw. Of course, it’s not as simple as placing

Akron Participates in Newly Published Study Modelling Cost of Goods for Allogeneic CAR T

Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic

A new 3D bio-printing method shows great potential for tissue engineering scaffolds

Electrospinning has been an attractive scaffold fabrication technique for over a decade capable of introducing micro-architectural ques to enhance tissue engineering modalities. Nonetheless, only a handful or architecturally relevant structures can be accomplished with this technique which require complex set-ups in order to be rendered properly. On the other hand, 3D Bio-Printing has emerged as

The immune system’s fountain of youth clears old cells in mice to slow aging

Aging is characterized by a functional decline in many physiological systems. Cellular senescence, a central component of aging, is a cell-intrinsic stress response programmed to impose stable cell-cycle arrest in damaged cells. These senescent cells are not completely dead but do suffer loss of function or irreparable damage, and they have been implicated in diseases

Microneedle patch delivers cardiac stem cells to promote heart repair following heart attack

Myocardial infarctions, commonly called heart attacks, affect thousands of people every year. Myocardial infarctions occur when a blockage in the arteries causes a decrease in blood flow to the heart. This leads to irreversible damage to the heart muscles, loss of cardiac cells, and scarring. Cell therapy seeks to regenerate lost cardiac cells with cardiac